Colorectal cancer
Drug research and approvals for colorectal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,565 studies of colorectal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 80 drug trials for it since 2013, FDA has 4 approved and 3 open orphan designations naming it, and the EU has 12 authorised medicines for it.
- Recruiting worldwide: 1,565
- Trials authorized in Canada: 80
- FDA orphan approvals: 4
- EU medicines: 12
Recruiting Now
Newest start dates first, of 1,565 recruiting on ClinicalTrials.gov ↗- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard…NCT07551596 · Phase 2 · National Cancer Institute (NCI) · starts May 25, 2027
- A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal…NCT06424522 · Not applicable · Ohio State University Comprehensive Cancer Center · starts Feb 15, 2027
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or…NCT07271355 · Phase 3 · City of Hope Medical Center · starts Jan 4, 2027
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)NCT07433673 · Phase 2 · Columbia University · starts Jan 1, 2027
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal…NCT07750158 · Phase 3 · Exelixis · starts Dec 18, 2026
- Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for…NCT07790718 · Not applicable · City of Hope Medical Center · starts Dec 16, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal CancerNCT07759921 · Not applicable · University of Colorado, Denver · starts Dec 1, 2026
- TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · Phase 1 · University of Pennsylvania · starts Dec 1, 2026
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerNCT07808151 · Phase 2 · Solstice Oncology, Inc. · starts Nov 30, 2026
Trials Authorized in Canada
The 10 newest of 80; search them all in Canada trials| Aug 19, 2026 | A phase Ib, multicenter, randomized study evaluating the safety and activity of gdc-7035 with anti-cancer therapies as first-line treatment in patients with…GDC-7035 (RO7782493) / PANITUMUMAB / OXALIPLATIN / IRINOTECAN / GEMCITABINE /… | Roche | Pending |
| Apr 24, 2026 | A randomized, open label, 3-arm phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in…PRECEMTABART TOCENTECAN (M9140) / AVASTIN (BEVACIZUMAB) / TIPIRACIL-TRIFLURIDINE | Merck KGaA | Ongoing |
| Mar 9, 2026 | A randomized, double blind, phase 3 study of standard-of-care chemotherapy and bevacizumab with or without inca33890 in the first line treatment of metastatic…INCA33890 / LEUCOVORIN / 5-FLUOROURACIL | Incyte Corporation | Ongoing |
| Dec 23, 2025 | An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of pf-08634404 in combination with chemotherapy versus…PF-08634404 (SSGJ-707) / ZIRABEV / FLUOROURACIL / LEUCOVORIN / OXALIPLATIN | Pfizer | Ongoing |
| Dec 12, 2025 | Rosetta crc-203: a blinded, randomized phase 2/3 study of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in…PUMITAMIG (BMS-986545; BNT327) | Bristol-Myers Squibb | Ongoing |
| Dec 10, 2025 | A randomized, active-controlled, double-blind, multicenter, phase 3 clinical folfox versus bevacizumab in combination with folfox for the first-line study…IVONESCIMAB | SUMMIT THERAPEUTICS INC. | Ongoing |
| Nov 25, 2025 | A phase II, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib with bevacizumab plus folfox or…INAVOLISIB (RO7113755) / BEVACIZUMAB / 5-FLUOROURACIL / IRINOTECAN / FOLINIC… | Roche | Closed |
| Aug 29, 2025 | A phase 3, randomized, open-label, multicenter clinical study to evaluate the safety and efficacy of mk-1084, cetuximab, and mfolfox6 versus mfolfox6 with or…MK-1084 / CETUXIMAB | Merck & Co. (MSD) | Ongoing |
| May 27, 2025 | A randomized, open label, multicenter, phase 2 study to evaluate the safety and efficacy of two dose levels of ono-4578 with opdivo® in combination with…ONO-4578 (BMS-986310) / OPDIVO (NIVOLUMAB) / ZIRABEV (BEVACIZUMAB) / LEUCOVORIN… | Ono Pharmaceutical | Ongoing |
| Mar 28, 2025 | Safely optimizing body weight with mifomelatide (tcmcb07) in patients with newly diagnosed colorectal cancer (crc) or pancreatic ductal adenocarcinoma (pdac)…MIFOMELATIDE (TCMCB07) | ENDEVICA BIO | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Jan 16, 2025 | Lumakrasin combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as… | Amgen Inc. | Approved |
| Jan 19, 2023 | Tukysain combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal… | Seagen Inc. | Approved |
| Apr 29, 2011 | FusilevFor use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer | Acrotech Biopharma LLC | Approved |
| Dec 12, 1991 | Leucovorin calciumFor use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. | Immunex Corporation | Approved |
| Jul 22, 2025 | small molecule that selectively and irreversibly inhibits…treatment of colorectal cancer (CRC) harboring KRAS p.G12C mutant protein | D3 Bio (Wuxi) Co., Ltd | Designated |
| Feb 22, 2024 | autologous logic-gated Tmod chimeric antigen receptor (CAR)…Treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses CEA and has lost HLA A*02 expression | A2 Biotherapeutics, Inc. | Designated |
| Jun 23, 1988 | Leucovorin calciumFor use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer. | Glaxo Wellcome Research and Development | Designated |
Medicines Authorised in the EU
Newest first| Jun 20, 2024 | Fruzaqlafruquintinib | Takeda Pharmaceuticals International AG Ireland | EMA ↗ |
| Sep 19, 2018 | Braftoviencorafenib | Pierre Fabre Medicament | EMA ↗ |
| Apr 25, 2016 | Lonsurftrifluridine;tipiracil | Les Laboratoires Servier | EMA ↗ |
| Aug 26, 2013 | Stivargaregorafenib | Bayer Pharma AG | EMA ↗ |
| Feb 1, 2013 | Zaltrapaflibercept | Sanofi Winthrop Industrie | EMA ↗ |
| Nov 19, 2012 | Capecitabine Medaccapecitabine · generic | medac Gesellschaft für klinische Spezialpräparate mbH | EMA ↗ |
| Apr 20, 2012 | Capecitabine Tevacapecitabine · generic | Teva Pharma B.V. | EMA ↗ |
| Apr 20, 2012 | Ecansya (previously Capecitabine Krka)capecitabine · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Apr 20, 2012 | Capecitabine Accordcapecitabine · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Dec 3, 2007 | Vectibixpanitumumab | Amgen Europe B.V. | EMA ↗ |
| Jun 29, 2004 | Erbituxcetuximab | Merck Europe B.V. | EMA ↗ |
| Feb 2, 2001 | Xelodacapecitabine | CHEPLAPHARM Arzneimittel GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA